Synthesis and biological evaluation of novel peptidomimetic inhibitors of the coronavirus 3C-like protease.

ABSTRACT: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and related variants, are responsible for the devastating coronavirus disease 2019 (COVID-19) pandemic. The SARS-CoV-2 main protease (Mpro) plays a central role in the replication of the virus and represents an attractive drug target. Herein, we report the discovery of novel SARS-CoV-2 Mpro covalent inhibitors, including highly effective compound NIP-22c which displays high potency against several key variants and clinically relevant nirmatrelvir Mpro E166V mutants.

SUBMITTER: Amblard F 

PROVIDER: S-EPMC11188152 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature